Shanghai Shen Lian Biomedical Corp (688098) — Tangible Net Worth Ratio
Shanghai Shen Lian Biomedical Corp (688098) has a Tangible Net Worth Ratio of 90.1% as of March 2026. This metric is calculated by deducting intangible assets (CN¥138.40 Million) from net assets (CN¥1.40 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Shanghai Shen Lian Biomedical Corp annual equity growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Shen Lian Biomedical Corp Tangible Net Worth Ratio (2013–2025)
This chart shows how Shanghai Shen Lian Biomedical Corp's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 90.1%, reflecting net assets of CN¥1.40 Billion with intangible assets of CN¥138.40 Million CNY. For live market cap and overall valuation, see 688098 stock market capitalisation.
Annual Tangible Net Worth Ratio for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Shen Lian Biomedical Corp from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore how much does Shanghai Shen Lian Biomedical Corp reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.0% | CN¥1.40 Billion | CN¥140.10 Million | CN¥1.54 Billion | ▼ -0.5 pp |
| 2024 | 90.5% | CN¥1.43 Billion | CN¥135.85 Million | CN¥1.55 Billion | ▼ -0.5 pp |
| 2023 | 91.0% | CN¥1.51 Billion | CN¥135.95 Million | CN¥1.59 Billion | ▼ -2.7 pp |
| 2022 | 93.6% | CN¥1.50 Billion | CN¥95.29 Million | CN¥1.61 Billion | ▼ -1.7 pp |
| 2021 | 95.4% | CN¥1.47 Billion | CN¥68.18 Million | CN¥1.60 Billion | ▼ -2.1 pp |
| 2020 | 97.5% | CN¥1.40 Billion | CN¥35.11 Million | CN¥1.51 Billion | ▲ +0.1 pp |
| 2019 | 97.4% | CN¥1.28 Billion | CN¥33.83 Million | CN¥1.45 Billion | ▲ +1.5 pp |
| 2018 | 95.9% | CN¥831.94 Million | CN¥34.44 Million | CN¥1.01 Billion | ▲ +2.3 pp |
| 2017 | 93.6% | CN¥549.27 Million | CN¥35.24 Million | CN¥692.19 Million | ▲ +1.3 pp |
| 2016 | 92.3% | CN¥465.47 Million | CN¥36.03 Million | CN¥607.79 Million | ▲ +3.9 pp |
| 2015 | 88.4% | CN¥317.41 Million | CN¥36.82 Million | CN¥490.32 Million | ▲ +4.0 pp |
| 2014 | 84.4% | CN¥241.57 Million | CN¥37.65 Million | CN¥528.89 Million | ▼ -13.8 pp |
| 2013 | 98.2% | CN¥327.59 Million | CN¥5.95 Million | CN¥531.53 Million | — |